| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Platelet Activation | 57 | 2024 | 643 | 9.140 |
Why?
|
| Blood Platelets | 81 | 2024 | 2464 | 8.830 |
Why?
|
| Platelet Function Tests | 27 | 2024 | 275 | 3.360 |
Why?
|
| Platelet Aggregation | 32 | 2022 | 769 | 3.350 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 11 | 2018 | 285 | 3.180 |
Why?
|
| Platelet Aggregation Inhibitors | 39 | 2021 | 2766 | 3.160 |
Why?
|
| Flow Cytometry | 32 | 2024 | 5879 | 2.480 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 24 | 2021 | 577 | 2.440 |
Why?
|
| Blood Platelet Disorders | 7 | 2024 | 60 | 2.290 |
Why?
|
| Ticlopidine | 19 | 2018 | 730 | 2.270 |
Why?
|
| Receptors, Purinergic P2Y12 | 12 | 2018 | 117 | 2.150 |
Why?
|
| Dinucleoside Phosphates | 6 | 2018 | 71 | 2.060 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 7 | 2024 | 144 | 1.910 |
Why?
|
| Adenosine Diphosphate | 18 | 2016 | 421 | 1.880 |
Why?
|
| P-Selectin | 20 | 2021 | 598 | 1.820 |
Why?
|
| Receptors, Purinergic P2Y1 | 7 | 2018 | 40 | 1.780 |
Why?
|
| Platelet-Rich Plasma | 6 | 2021 | 180 | 1.650 |
Why?
|
| Hemostasis | 7 | 2024 | 467 | 1.570 |
Why?
|
| Thiophenes | 12 | 2018 | 570 | 1.540 |
Why?
|
| Purinergic P2 Receptor Antagonists | 5 | 2013 | 67 | 1.370 |
Why?
|
| Receptor, PAR-1 | 4 | 2021 | 109 | 1.330 |
Why?
|
| Platelet Count | 8 | 2021 | 784 | 1.320 |
Why?
|
| Piperazines | 13 | 2013 | 2547 | 1.210 |
Why?
|
| CD40 Ligand | 8 | 2023 | 528 | 1.140 |
Why?
|
| Aspirin | 16 | 2018 | 3135 | 1.090 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 5 | 2018 | 245 | 1.020 |
Why?
|
| Anemia, Sickle Cell | 8 | 2021 | 1063 | 0.930 |
Why?
|
| Serotonin | 3 | 2024 | 1045 | 0.880 |
Why?
|
| Thrombasthenia | 6 | 2022 | 21 | 0.860 |
Why?
|
| Sudden Infant Death | 2 | 2024 | 293 | 0.860 |
Why?
|
| 14-3-3 Proteins | 1 | 2024 | 221 | 0.840 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 2 | 2013 | 31 | 0.820 |
Why?
|
| Integrin beta3 | 4 | 2018 | 120 | 0.760 |
Why?
|
| Immunoglobulin Fab Fragments | 8 | 2013 | 443 | 0.730 |
Why?
|
| Coronary Thrombosis | 4 | 2018 | 440 | 0.730 |
Why?
|
| Epidermal Growth Factor | 4 | 2021 | 697 | 0.700 |
Why?
|
| Blood Coagulation | 11 | 2022 | 1168 | 0.690 |
Why?
|
| Thromboxane B2 | 4 | 2017 | 143 | 0.690 |
Why?
|
| Immunophenotyping | 6 | 2023 | 1865 | 0.680 |
Why?
|
| Electricity | 3 | 2021 | 173 | 0.670 |
Why?
|
| Platelet Membrane Glycoproteins | 16 | 2016 | 282 | 0.650 |
Why?
|
| Drug Resistance | 5 | 2009 | 1592 | 0.610 |
Why?
|
| Hematologic Agents | 1 | 2018 | 39 | 0.600 |
Why?
|
| Thrombocytopenia | 5 | 2021 | 1172 | 0.590 |
Why?
|
| Cyclooxygenase 1 | 2 | 2009 | 98 | 0.590 |
Why?
|
| Megakaryocytes | 2 | 2022 | 557 | 0.590 |
Why?
|
| Hemorrhage | 7 | 2021 | 3464 | 0.590 |
Why?
|
| Dog Diseases | 1 | 2018 | 143 | 0.580 |
Why?
|
| Thrombopoiesis | 1 | 2018 | 160 | 0.550 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2019 | 1656 | 0.550 |
Why?
|
| Platelet Adhesiveness | 8 | 2016 | 154 | 0.540 |
Why?
|
| Cell-Derived Microparticles | 4 | 2021 | 160 | 0.500 |
Why?
|
| Acute Coronary Syndrome | 6 | 2018 | 2183 | 0.460 |
Why?
|
| Cytoplasmic Granules | 3 | 2022 | 573 | 0.420 |
Why?
|
| Adenosine | 2 | 2017 | 813 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 21 | 2013 | 9237 | 0.380 |
Why?
|
| Omeprazole | 1 | 2012 | 106 | 0.380 |
Why?
|
| Thiazoles | 1 | 2018 | 1528 | 0.370 |
Why?
|
| Humans | 127 | 2024 | 766019 | 0.350 |
Why?
|
| Leukocytes | 8 | 2016 | 2030 | 0.340 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2009 | 13 | 0.340 |
Why?
|
| Proton Pump Inhibitors | 2 | 2013 | 551 | 0.340 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2021 | 614 | 0.340 |
Why?
|
| Receptors, Thrombin | 4 | 2022 | 130 | 0.340 |
Why?
|
| Liver Diseases | 1 | 2018 | 1304 | 0.340 |
Why?
|
| Thrombin | 9 | 2021 | 600 | 0.330 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2023 | 131 | 0.330 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1480 | 0.320 |
Why?
|
| Pyrazoles | 5 | 2019 | 2031 | 0.300 |
Why?
|
| Microfilament Proteins | 6 | 2017 | 1130 | 0.300 |
Why?
|
| Clot Retraction | 1 | 2007 | 13 | 0.300 |
Why?
|
| Communication | 2 | 2022 | 3908 | 0.300 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 3692 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2018 | 10737 | 0.280 |
Why?
|
| Cardiology | 1 | 2018 | 1694 | 0.280 |
Why?
|
| Factor Va | 2 | 2021 | 10 | 0.270 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 3801 | 0.260 |
Why?
|
| Cell Adhesion Molecules | 7 | 2017 | 1610 | 0.260 |
Why?
|
| Arachidonic Acid | 3 | 2006 | 429 | 0.250 |
Why?
|
| Coronary Artery Disease | 8 | 2016 | 6540 | 0.250 |
Why?
|
| Fibrinogen | 7 | 2006 | 894 | 0.250 |
Why?
|
| Prodrugs | 1 | 2007 | 274 | 0.250 |
Why?
|
| Blood Coagulation Factors | 1 | 2007 | 372 | 0.240 |
Why?
|
| Cross-Over Studies | 6 | 2017 | 2108 | 0.240 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 246 | 0.230 |
Why?
|
| Dogs | 7 | 2018 | 3825 | 0.230 |
Why?
|
| Double-Blind Method | 12 | 2019 | 12426 | 0.220 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 596 | 0.220 |
Why?
|
| Peptides | 4 | 2013 | 4338 | 0.220 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 4248 | 0.220 |
Why?
|
| Thrombelastography | 3 | 2018 | 196 | 0.210 |
Why?
|
| Cardiovascular Diseases | 8 | 2015 | 15639 | 0.210 |
Why?
|
| Male | 58 | 2024 | 363880 | 0.210 |
Why?
|
| Female | 56 | 2024 | 396174 | 0.200 |
Why?
|
| Phosphoproteins | 5 | 2017 | 2445 | 0.200 |
Why?
|
| Benzoates | 2 | 2015 | 213 | 0.200 |
Why?
|
| Tyrosine | 3 | 2003 | 1427 | 0.200 |
Why?
|
| Hydrazines | 2 | 2015 | 223 | 0.200 |
Why?
|
| Annexin A5 | 2 | 2015 | 102 | 0.190 |
Why?
|
| Gaucher Disease | 1 | 2021 | 110 | 0.180 |
Why?
|
| Eczema | 1 | 2023 | 244 | 0.180 |
Why?
|
| Calgranulin A | 1 | 2021 | 80 | 0.180 |
Why?
|
| Kinetics | 7 | 2017 | 6273 | 0.180 |
Why?
|
| Calgranulin B | 1 | 2021 | 87 | 0.180 |
Why?
|
| Monocytes | 6 | 2015 | 2591 | 0.180 |
Why?
|
| Indicators and Reagents | 1 | 2021 | 456 | 0.170 |
Why?
|
| NFATC Transcription Factors | 1 | 2022 | 391 | 0.170 |
Why?
|
| Electric Stimulation | 2 | 2015 | 1736 | 0.170 |
Why?
|
| Middle Aged | 40 | 2021 | 223035 | 0.160 |
Why?
|
| Fibrinolytic Agents | 4 | 2016 | 2077 | 0.160 |
Why?
|
| Phenotype | 7 | 2023 | 16714 | 0.160 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2018 | 50 | 0.160 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2018 | 51 | 0.150 |
Why?
|
| Case-Control Studies | 10 | 2018 | 22230 | 0.150 |
Why?
|
| Cattle | 7 | 2019 | 3801 | 0.150 |
Why?
|
| Adenosine Monophosphate | 2 | 2017 | 232 | 0.150 |
Why?
|
| Hypothermia, Induced | 1 | 2003 | 754 | 0.150 |
Why?
|
| Coronary Restenosis | 1 | 2021 | 396 | 0.150 |
Why?
|
| Area Under Curve | 2 | 2013 | 1638 | 0.150 |
Why?
|
| Electrochemical Techniques | 1 | 2018 | 90 | 0.150 |
Why?
|
| Phosphatidylserines | 3 | 2021 | 185 | 0.150 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2018 | 213 | 0.150 |
Why?
|
| Drug Interactions | 2 | 2013 | 1419 | 0.150 |
Why?
|
| Thrombosis | 6 | 2024 | 2953 | 0.140 |
Why?
|
| Hemophilia A | 1 | 2021 | 357 | 0.140 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 197 | 0.140 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 6308 | 0.140 |
Why?
|
| Calpain | 1 | 2017 | 146 | 0.140 |
Why?
|
| Asphyxia | 1 | 2017 | 60 | 0.140 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 683 | 0.130 |
Why?
|
| Adult | 32 | 2021 | 223110 | 0.130 |
Why?
|
| Blood Specimen Collection | 2 | 2016 | 238 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2018 | 384 | 0.130 |
Why?
|
| Receptors, Purinergic P2X1 | 1 | 2015 | 8 | 0.130 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2015 | 24 | 0.130 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 968 | 0.130 |
Why?
|
| Octoxynol | 1 | 2015 | 76 | 0.130 |
Why?
|
| Drug Stability | 1 | 2015 | 289 | 0.120 |
Why?
|
| Cell Adhesion | 5 | 2003 | 3089 | 0.120 |
Why?
|
| Antibodies | 2 | 2023 | 2415 | 0.120 |
Why?
|
| Gastroparesis | 1 | 2017 | 143 | 0.120 |
Why?
|
| Hemoglobins | 1 | 2021 | 1531 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 4853 | 0.120 |
Why?
|
| Factor V | 2 | 2008 | 168 | 0.120 |
Why?
|
| Integrins | 4 | 1993 | 838 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2010 | 1721 | 0.110 |
Why?
|
| Collagen | 5 | 2009 | 2618 | 0.110 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 482 | 0.110 |
Why?
|
| Drug Monitoring | 3 | 2021 | 961 | 0.110 |
Why?
|
| Diabetic Neuropathies | 1 | 2017 | 409 | 0.110 |
Why?
|
| Stereoisomerism | 1 | 2014 | 612 | 0.110 |
Why?
|
| Time Factors | 9 | 2018 | 40100 | 0.100 |
Why?
|
| Aryldialkylphosphatase | 1 | 2013 | 64 | 0.100 |
Why?
|
| Methionine | 2 | 1986 | 569 | 0.100 |
Why?
|
| Pain | 2 | 2021 | 5089 | 0.100 |
Why?
|
| Peptide Fragments | 7 | 2015 | 5125 | 0.100 |
Why?
|
| Reference Values | 2 | 2012 | 4909 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2013 | 1404 | 0.100 |
Why?
|
| Cell Line | 3 | 2016 | 15545 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 426 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2019 | 12235 | 0.100 |
Why?
|
| International Cooperation | 1 | 2018 | 1433 | 0.100 |
Why?
|
| Treatment Outcome | 11 | 2019 | 65203 | 0.100 |
Why?
|
| Light | 2 | 2015 | 1358 | 0.100 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 3051 | 0.100 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 995 | 0.090 |
Why?
|
| Consensus | 1 | 2021 | 3200 | 0.090 |
Why?
|
| Infant | 4 | 2024 | 36424 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10431 | 0.090 |
Why?
|
| Young Adult | 13 | 2021 | 59858 | 0.090 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2015 | 386 | 0.090 |
Why?
|
| Vascular Patency | 3 | 2009 | 914 | 0.090 |
Why?
|
| Thromboxane A2 | 2 | 2008 | 87 | 0.090 |
Why?
|
| Platelet Activating Factor | 1 | 2011 | 142 | 0.090 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2013 | 222 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 1794 | 0.090 |
Why?
|
| Neutrophils | 5 | 2022 | 3770 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 1331 | 0.090 |
Why?
|
| Animals | 27 | 2022 | 168801 | 0.090 |
Why?
|
| Receptors, Purinergic P2X | 1 | 2009 | 9 | 0.090 |
Why?
|
| Diabetic Angiopathies | 2 | 2016 | 805 | 0.090 |
Why?
|
| Adolescent | 11 | 2021 | 88808 | 0.090 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2009 | 25 | 0.080 |
Why?
|
| Drug Substitution | 1 | 2012 | 292 | 0.080 |
Why?
|
| Parathyroid Hormone | 3 | 1986 | 1790 | 0.080 |
Why?
|
| Serotonin Antagonists | 1 | 2009 | 146 | 0.080 |
Why?
|
| Aged | 18 | 2019 | 171170 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 1195 | 0.080 |
Why?
|
| Hydroxyurea | 2 | 2021 | 284 | 0.080 |
Why?
|
| Thromboplastin | 2 | 2007 | 289 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 4423 | 0.080 |
Why?
|
| Cell Separation | 2 | 2005 | 1718 | 0.080 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 301 | 0.070 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2007 | 14 | 0.070 |
Why?
|
| Biotransformation | 1 | 2007 | 165 | 0.070 |
Why?
|
| ROC Curve | 1 | 2015 | 3614 | 0.070 |
Why?
|
| Sepsis | 1 | 2022 | 2604 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 20135 | 0.070 |
Why?
|
| Predictive Value of Tests | 6 | 2015 | 15403 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3499 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2019 | 3050 | 0.070 |
Why?
|
| Calcium | 4 | 2021 | 5770 | 0.070 |
Why?
|
| Chest Pain | 1 | 2014 | 1101 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2013 | 8290 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2013 | 615 | 0.070 |
Why?
|
| Epitopes | 5 | 1992 | 2523 | 0.070 |
Why?
|
| Infant, Newborn | 4 | 2024 | 26379 | 0.070 |
Why?
|
| Receptors, Peptide | 1 | 1988 | 280 | 0.070 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2007 | 452 | 0.070 |
Why?
|
| Glycoproteins | 4 | 2002 | 2197 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 26280 | 0.070 |
Why?
|
| Cystic Fibrosis | 2 | 2007 | 1284 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 361 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2023 | 3405 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2015 | 11642 | 0.070 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2006 | 68 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2013 | 3636 | 0.070 |
Why?
|
| Morpholines | 1 | 2009 | 584 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2915 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2018 | 3955 | 0.070 |
Why?
|
| Oligopeptides | 5 | 1993 | 1195 | 0.060 |
Why?
|
| Withholding Treatment | 1 | 2010 | 619 | 0.060 |
Why?
|
| Receptors, Immunologic | 2 | 1989 | 1416 | 0.060 |
Why?
|
| Antigens, Surface | 2 | 1986 | 1616 | 0.060 |
Why?
|
| Blood Cells | 1 | 2007 | 307 | 0.060 |
Why?
|
| Dalteparin | 2 | 2003 | 44 | 0.060 |
Why?
|
| Wound Healing | 1 | 2016 | 2795 | 0.060 |
Why?
|
| Cell Communication | 3 | 2022 | 1660 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2018 | 42509 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5752 | 0.060 |
Why?
|
| Protein Conformation | 5 | 2001 | 3947 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 3445 | 0.060 |
Why?
|
| Heterozygote | 2 | 2011 | 2796 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2018 | 4854 | 0.060 |
Why?
|
| Benzamides | 1 | 2009 | 1376 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2015 | 4496 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2018 | 6611 | 0.050 |
Why?
|
| Binding, Competitive | 4 | 2001 | 1140 | 0.050 |
Why?
|
| Crotalid Venoms | 2 | 1993 | 29 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2018 | 9351 | 0.050 |
Why?
|
| Tissue Fixation | 2 | 2001 | 245 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2015 | 9655 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2015 | 3684 | 0.050 |
Why?
|
| Laboratories | 1 | 2007 | 462 | 0.050 |
Why?
|
| Endothelium | 2 | 2003 | 768 | 0.050 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2006 | 481 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2006 | 433 | 0.050 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2023 | 163 | 0.050 |
Why?
|
| Amino Acid Sequence | 11 | 1992 | 13400 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2013 | 2694 | 0.050 |
Why?
|
| Gene Expression | 1 | 2015 | 7581 | 0.050 |
Why?
|
| Genotype | 5 | 2017 | 13027 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2017 | 23600 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2009 | 11506 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1926 | 0.050 |
Why?
|
| Protein Binding | 3 | 2002 | 9302 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3594 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2001 | 51 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 1852 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 978 | 0.050 |
Why?
|
| Antisickling Agents | 1 | 2021 | 72 | 0.050 |
Why?
|
| Comorbidity | 1 | 2015 | 10577 | 0.040 |
Why?
|
| Coronary Disease | 3 | 2005 | 5914 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 1984 | 740 | 0.040 |
Why?
|
| Child | 4 | 2018 | 80567 | 0.040 |
Why?
|
| Hirudins | 1 | 2001 | 179 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2021 | 404 | 0.040 |
Why?
|
| Hemostatics | 1 | 2003 | 247 | 0.040 |
Why?
|
| Rats | 3 | 2015 | 23718 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 2593 | 0.040 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 18321 | 0.040 |
Why?
|
| Hypertension | 1 | 2019 | 8609 | 0.040 |
Why?
|
| Inflammation | 5 | 2022 | 10858 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6506 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2007 | 2051 | 0.040 |
Why?
|
| Factor VIII | 1 | 2021 | 347 | 0.040 |
Why?
|
| Heparin | 3 | 2003 | 1635 | 0.040 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 1218 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2003 | 893 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 1527 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2006 | 2352 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2007 | 4133 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2002 | 1753 | 0.040 |
Why?
|
| Epinephrine | 3 | 2008 | 782 | 0.040 |
Why?
|
| Calcitonin | 4 | 1980 | 326 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2012 | 682 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 1897 | 0.040 |
Why?
|
| Recurrence | 2 | 2009 | 8494 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 94 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 2504 | 0.030 |
Why?
|
| Dosage Forms | 1 | 2017 | 55 | 0.030 |
Why?
|
| Risk Factors | 4 | 2018 | 74837 | 0.030 |
Why?
|
| Actigraphy | 1 | 2021 | 526 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1729 | 0.030 |
Why?
|
| Molecular Sequence Data | 9 | 1992 | 17597 | 0.030 |
Why?
|
| Ligands | 4 | 1991 | 3274 | 0.030 |
Why?
|
| Binding Sites | 6 | 1993 | 6002 | 0.030 |
Why?
|
| E-Selectin | 1 | 2018 | 576 | 0.030 |
Why?
|
| Smoking | 2 | 2013 | 9077 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2014 | 54804 | 0.030 |
Why?
|
| Biological Availability | 1 | 2017 | 387 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2001 | 822 | 0.030 |
Why?
|
| Cell Division | 2 | 2003 | 4467 | 0.030 |
Why?
|
| Paresis | 1 | 2017 | 177 | 0.030 |
Why?
|
| Edetic Acid | 2 | 2004 | 274 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 1998 | 273 | 0.030 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2017 | 326 | 0.030 |
Why?
|
| Chromatography, Affinity | 3 | 1992 | 521 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 1967 | 0.030 |
Why?
|
| Membrane Proteins | 3 | 2000 | 7850 | 0.030 |
Why?
|
| Heredity | 1 | 2015 | 149 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 7870 | 0.030 |
Why?
|
| Placebos | 1 | 2018 | 1659 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 158 | 0.030 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1993 | 48 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2007 | 18965 | 0.030 |
Why?
|
| Exocytosis | 1 | 2015 | 323 | 0.030 |
Why?
|
| Fibrin | 1 | 2016 | 513 | 0.030 |
Why?
|
| Autopsy | 1 | 2017 | 1011 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14644 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 1321 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1588 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8723 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12061 | 0.030 |
Why?
|
| Brain Stem | 1 | 2017 | 852 | 0.020 |
Why?
|
| Coronary Circulation | 2 | 2009 | 1601 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 1991 | 136 | 0.020 |
Why?
|
| Erythroid Cells | 1 | 2013 | 237 | 0.020 |
Why?
|
| Carbazoles | 1 | 2013 | 229 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2011 | 83 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 1670 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2001 | 4025 | 0.020 |
Why?
|
| Cell Shape | 1 | 2011 | 372 | 0.020 |
Why?
|
| United States | 1 | 2018 | 72918 | 0.020 |
Why?
|
| Cell Membrane | 5 | 2005 | 3635 | 0.020 |
Why?
|
| Drug Inverse Agonism | 1 | 2009 | 11 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2013 | 562 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2009 | 61 | 0.020 |
Why?
|
| Hematocrit | 1 | 2011 | 622 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1605 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 637 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 6057 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 1990 | 269 | 0.020 |
Why?
|
| Oxidation-Reduction | 2 | 1986 | 2223 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 1742 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 13082 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 1167 | 0.020 |
Why?
|
| Behavior | 1 | 2011 | 537 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15882 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1988 | 167 | 0.020 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2008 | 83 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1990 | 508 | 0.020 |
Why?
|
| Body Temperature | 1 | 2011 | 781 | 0.020 |
Why?
|
| Temperature | 2 | 2011 | 2227 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1990 | 1061 | 0.020 |
Why?
|
| Extracellular Space | 2 | 1986 | 563 | 0.020 |
Why?
|
| Fibronectins | 1 | 1991 | 721 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 877 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 684 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2007 | 95 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 774 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 1990 | 351 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 3106 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1774 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2016 | 2389 | 0.020 |
Why?
|
| Mice | 3 | 2022 | 81838 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 1996 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 2271 | 0.020 |
Why?
|
| Methanol | 1 | 1986 | 91 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2005 | 238 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2844 | 0.020 |
Why?
|
| Blotting, Western | 3 | 2005 | 5019 | 0.020 |
Why?
|
| Cytoplasm | 2 | 1986 | 1498 | 0.020 |
Why?
|
| Insulin | 1 | 2019 | 6603 | 0.020 |
Why?
|
| Alprostadil | 1 | 2005 | 86 | 0.020 |
Why?
|
| Alleles | 2 | 2013 | 6892 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 2005 | 283 | 0.010 |
Why?
|
| Destrin | 1 | 2004 | 10 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3431 | 0.010 |
Why?
|
| Cyanogen Bromide | 1 | 1984 | 75 | 0.010 |
Why?
|
| Cysteamine | 1 | 1984 | 24 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 8114 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1986 | 964 | 0.010 |
Why?
|
| Factor Xa | 1 | 2005 | 165 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2004 | 91 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 14747 | 0.010 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2004 | 42 | 0.010 |
Why?
|
| Amino Acids | 2 | 1992 | 1711 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2011 | 1365 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 109 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2013 | 2574 | 0.010 |
Why?
|
| Polysomnography | 1 | 2011 | 1868 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2011 | 838 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2013 | 2590 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3586 | 0.010 |
Why?
|
| Ibuprofen | 1 | 2005 | 228 | 0.010 |
Why?
|
| Species Specificity | 1 | 2007 | 2406 | 0.010 |
Why?
|
| Methods | 1 | 2003 | 1061 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 380 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 1378 | 0.010 |
Why?
|
| Solubility | 1 | 2004 | 1077 | 0.010 |
Why?
|
| Dipeptides | 1 | 2004 | 386 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14457 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 39233 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 2395 | 0.010 |
Why?
|
| Atherectomy | 1 | 2001 | 41 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 392 | 0.010 |
Why?
|
| Kidney | 2 | 2010 | 7072 | 0.010 |
Why?
|
| Kidney Cortex | 1 | 1981 | 167 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 10380 | 0.010 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 1884 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1986 | 2476 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2001 | 202 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 2232 | 0.010 |
Why?
|
| Platelet Storage Pool Deficiency | 1 | 2000 | 3 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1467 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 750 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 249 | 0.010 |
Why?
|
| Blood | 1 | 2003 | 597 | 0.010 |
Why?
|
| Vitamin E | 1 | 2005 | 872 | 0.010 |
Why?
|
| Genome, Human | 1 | 2013 | 4442 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 2003 | 519 | 0.010 |
Why?
|
| Models, Biological | 1 | 2016 | 9446 | 0.010 |
Why?
|
| Blood Banks | 1 | 2000 | 108 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2001 | 682 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 24272 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2009 | 4188 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22339 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1984 | 3584 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 3270 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2227 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1981 | 760 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4565 | 0.010 |
Why?
|
| Calibration | 1 | 2000 | 813 | 0.010 |
Why?
|
| Quality Control | 1 | 2000 | 835 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2002 | 704 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9507 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 1806 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 1688 | 0.010 |
Why?
|
| Mutation | 2 | 1992 | 30210 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2011 | 4527 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8529 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8524 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12822 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1979 | 2010 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2006 | 3093 | 0.010 |
Why?
|
| Base Sequence | 3 | 1992 | 12405 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2001 | 2076 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 5939 | 0.010 |
Why?
|
| Radioimmunoassay | 3 | 1980 | 860 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 41677 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 7237 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2011 | 13042 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 18075 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4342 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 13614 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1992 | 6492 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 29905 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 18382 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1991 | 643 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 416 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 12772 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 11035 | 0.010 |
Why?
|
| Vitronectin | 1 | 1989 | 40 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1056 | 0.010 |
Why?
|
| Receptors, Vitronectin | 1 | 1989 | 48 | 0.010 |
Why?
|
| CHO Cells | 1 | 1992 | 1373 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 1724 | 0.000 |
Why?
|
| Primary Myelofibrosis | 1 | 1990 | 209 | 0.000 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 1677 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 2469 | 0.000 |
Why?
|
| Cricetinae | 1 | 1992 | 2413 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1989 | 812 | 0.000 |
Why?
|
| Aspartic Acid | 1 | 1990 | 575 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1990 | 1430 | 0.000 |
Why?
|
| Brain Ischemia | 1 | 2000 | 3002 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1989 | 2161 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 59497 | 0.000 |
Why?
|
| DNA | 2 | 1992 | 7192 | 0.000 |
Why?
|
| Thyroid Neoplasms | 1 | 1979 | 2355 | 0.000 |
Why?
|
| Sialoglycoproteins | 1 | 1986 | 313 | 0.000 |
Why?
|
| Microscopy, Fluorescence | 1 | 1993 | 2626 | 0.000 |
Why?
|
| Lung Neoplasms | 2 | 1980 | 13483 | 0.000 |
Why?
|
| Pancreas | 1 | 1991 | 1699 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1992 | 4112 | 0.000 |
Why?
|
| RNA | 1 | 1992 | 2715 | 0.000 |
Why?
|
| Radioligand Assay | 1 | 1980 | 365 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1987 | 3733 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1979 | 631 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1979 | 2077 | 0.000 |
Why?
|
| Carcinoma | 2 | 1980 | 2313 | 0.000 |
Why?
|
| Substrate Specificity | 1 | 1981 | 1751 | 0.000 |
Why?
|
| Parathyroid Glands | 1 | 1978 | 521 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1979 | 419 | 0.000 |
Why?
|
| Retina | 1 | 1986 | 2646 | 0.000 |
Why?
|
| Biological Assay | 1 | 1978 | 626 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1979 | 1227 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1980 | 4047 | 0.000 |
Why?
|
| Thyroidectomy | 1 | 1978 | 912 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1979 | 1440 | 0.000 |
Why?
|
| Adenocarcinoma | 2 | 1980 | 6361 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1979 | 4860 | 0.000 |
Why?
|
| Sex Factors | 1 | 1978 | 10611 | 0.000 |
Why?
|
| Aging | 1 | 1978 | 8723 | 0.000 |
Why?
|